Abstract
CCL21, a member of the CC-type chemokine family, has been used in anti-tumor research and clinical treatment because of its chemotaxis and activation of dendritic cells (DCs) and immune effector cells. Since then, effective immunotherapeutic strategies and improvements based on CCL21 have emerged to enhance anti-tumor effects. This article summarizes the anti-tumor immune mechanism and application of CCL21 to provide reference for further research and clinical application. Key words: Chemokine CCL21; Tumor; Immunotherapy; Application
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
